Doubling up: How ASX biotechs are multiplying their impact
LTR Pharma leveraging proven intranasal platform for erectile dysfunction treatment to target non-invasive relief for patients with swallowing difficulties
From concussion to Alzheimer's the CogState Cognigram digital cognitive assessment system is used by physicians to monitor brain function
As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to find smarter ways to stretch the value of their existing assets.
Whether it's repurposing a drug delivery platform, extending the reach of a diagnostic tool or developing next-generation compounds that act on the same biological pathway to treat other conditions, these companies are using proven science as a launchpad into broader clinical territory.
The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss.
Blockbusters like Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) are now reshaping treatment for obesity and related conditions.
It's a compelling demonstration of how one well-validated mechanism of action can be leveraged across multiple disease areas in turn lowering development risk, tapping into existing safety and efficacy data, and accelerating time to market.
For ASX healthcare companies navigating tighter capital conditions, similar strategies are proving to be a smart and resourceful way to unlock broader clinical value from their existing platforms.
LTR Pharma rises above ED with nasal spray tech targeting broader conditions
Developer of a nasal spray treatment for erectile dysfunction (ED), LTR Pharma (ASX:LTP) has turned to a secondary program using its innovative intranasal delivery platform but this time for oesophageal motility disorders (OMD).
In May, LTR Pharma announced it had inked a collaborative development agreement with US-based Strategic Drug Solutions (SDS) to develop Oroflow a spray for OMD – a group of conditions that cause impaired swallowing (dysphagia).
The program leverages LTR's proven proprietary intranasal delivery platform and foundational work from its Spontan and Roxus ED treatments to target rapid symptom relief for patients with swallowing difficulties, potentially offering a non-invasive alternative to current treatments.
Oroflow aims to deliver relief in 10 minutes, bypassing swallowing barriers and offering a compelling althernative to treatments including invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections.
LTR Pharma is addressing a $4.5 billion OMD market projected to reach $8.1 bn by 2034 with the company announcing in its latest quarterly report that proof-of-concept testing preparations were underway.
LTR Pharma executive chairman Lee Rodne said Oroflow represented an exciting expansion of its nasal spray platform.
"For patients with swallowing difficulties, oral medications present obvious challenges for patients," he said.
"Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief.
Neuren targeting broad set of neurological conditions
Neuren Pharmaceuticals (ASX:NEU) is another standout. The company and US partner Acadia was in 2023 granted the first US Food and Drug Administration (FDA) approval for a drug to treat Rett syndrome, a rare neurological disorder mostly affecting girls and emerging in infancy.
Trofinetide, marketed as Daybue, is a synthetic analog of part of the hormone insulin-like growth factor 1 (IGF-1), which is a potent regulator of central nervous system development.
Neuren is now advancing NNZ-2591, which also targets IGF-1. Building on the scientific foundation of trofinetide, NNZ-2591 is structurally optimised to improve brain penetration, enhance tolerability, and expand therapeutic reach across a broader set of neurodevelopmental conditions.
Using a strategy that targets multiple indications from one compound, Neuren aims to accelerate development while reducing R&D expenses.
Currently in phase II trials, NNZ-2591 could open new treatment avenues for other underserved neurodevelopmental conditions like Phelan-McDermid, Angelman, and Pitt-Hopkins syndromes.
The company is preparing to start a phase III study of NNZ-2591 for its most advanced program Phelin McDermid. It also plans to consult with the FDA this year to establish a clinical path for NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), which results from a baby's brain not getting enough oxygen or blood flow before, or shortly after, birth.
"We believe the mechanism of action of NNZ-2591 can be broadly applicable to neurodevelopmental disorders, independent of the genetic origin," CEO Jon Pilcher told Stockhead.
"We are striving to be successful in multiple settings, for the benefit of both the impacted families and our shareholders."
Tracking cognition from concussion to Alzheimer's
From footy fields to neurology clinics, the CogState (ASX:CGS) Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of brain function – including processing speed, attention, visual learning, working memory and executive function.
The test can assess cognition at a single point in time or track changes over multiple assessments. You may have heard of it referred to as the Cogstate concussion test in footy coverage. However, Cognigram has since evolved into a widely used tool in healthcare and research.
Cogstate is riding a wave of global demand for cognition-related clinical trials, particularly in the race to treat Alzheimer's disease and related dementias.
The company recently upgraded its financial guidance for FY25, reflecting strong performance and improved outlook across key financial metrics.
Full-year profit before tax is forecast to be in the range of $12-14m, an improvement of 69% to 97% on FY24.
"We are now using Cognigram, which is the same cognitive assessment used to assess AFL footballers for concussion, to prescreen for clinical trials in the earlier stages of Alzheimer's," CEO Brad O'Connor told Stockhead.
"We have a contract with a large pharmaceutical company screening for 20,000 patients in the community to find those that might be appropriate to include in their very early stage Alzheimer's trials.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
an hour ago
- ABC News
eSafety sommissioner says Youtube turning blind eye to child abuse
Australia's internet watchdog has accused the world's biggest social media firms of still "turning a blind eye" to online child sex abuse material on their platforms, and said YouTube in particular had been unresponsive to its enquiries. In a report released on Wednesday, the eSafety Commissioner said YouTube, along with Apple, failed to track the number of user reports it received of child sex abuse appearing on their platforms and also could not say how long it took them to respond to such reports. The federal government decided last week to include YouTube in its world-first social media ban for teenagers, following the commissioner's advice to overturn its planned exemption for the Alphabet-owned Google's video-sharing site. "When left to their own devices, these companies aren't prioritising the protection of children and are seemingly turning a blind eye to crimes occurring on their services," eSafety Commissioner Julie Inman Grant said in a statement. "No other consumer-facing industry would be given the licence to operate by enabling such heinous crimes against children on their premises, or services." Google has said previously that abuse material has no place on its platforms and that it uses a range of industry-standard techniques to identify and remove such material. Meta — owner of Facebook, Instagram and Threads, three of the biggest platforms with more than three billion users worldwide — has said it prohibits graphic videos. The eSafety Commissioner, an office set up to protect internet users, has mandated Apple, Discord, Google, Meta, Microsoft, Skype, Snap and WhatsApp report on the measures they take to address child exploitation and abuse material in Australia. The report on their responses so far found a "range of safety deficiencies on their services which increases the risk that child sexual exploitation and abuse material and activity appear on the services". Safety gaps included failures to detect and prevent live-streaming of the material or block links to known child abuse material, as well as inadequate reporting mechanisms. It said platforms were also not using hash-matching technology on all parts of their services to identify images of child sexual abuse by checking them against a database. Google has maintained its anti-abuse measures include hash-matching technology and artificial intelligence. The Australian regulator said some providers had not made improvements to address these safety gaps on their services despite it putting them on notice in previous years. "In the case of Apple services and Google's YouTube, they didn't even answer our questions about how many user reports they received about child sexual abuse on their services or details of how many trust and safety personnel Apple and Google have on-staff," Ms Inman Grant said. Reuters
News.com.au
3 hours ago
- News.com.au
Weekend auction wrap: Sydney family smashes neighbour's record
A home in Sydney's northwest has sold for a suburb record, smashing the price paid for a home owned by the neighbours - the previous highest price in the area. The property on Anthony Rd sold for $4.7 million, setting a new record for a house sale in West Ryde. The auction saw the sellers pcoket a price $300,000 above their $4.4 million reserve. It has come amid rising auction activity that suggests Sydney is due another round of stellar growth in home prices. Auction clearance rates have been above 70 per cent for weeks, with preliminary figures showing nearly three quarters of auctions last week produced a sale. Historically, this kind of success rate over successive weeks has coincided with widespread price rises. Pello Northern Suburbs sales agent Michael Dowling said the West Ryde auction was 'really competitive' with bidding starting at $3.8 million. 'The previous highest sale in West Ryde was the house next door, and that sold for $4.19 about two years ago,' he said. 'So we knew it was going to be better than that, but I didn't think it was going to be $510,000 better than that.' Mr Dowling said the home sold to a mother and two sons moving from Cheltenham who wanted a more spacious home that was ready to move in to. 'A lot of people in our area want that move-in ready feel, rather than going through the hassle and the inconvenience of dealing with council,' he said. 'A lot of people just want that finished product now.' Based on results received so far, about 75 per cent of Sydney auctions were successful last week. Auction clearance rates above 70 per cent have historically correlated with rises in prices across the Sydney market as a whole. Ray White NSW head of auctions Dave McMahon said the first weekend of August saw a 25 per cent decrease in scheduled auctions from the week prior. 'The notable difference was that only half of them proceeded through the day,' he said. 'With stock levels low, agents have been more open to entertaining offers prior with circa 15-20 per cent selling before auction day. 'Despite lower auction numbers today, we continued to see spirited competition from buyers with an average of 5.8 registered and 3.6 actively bidding.' Two auctions hosted by Scerri Auctions auctioneer Fadi Hajjar on Friday were moved inside to Saliba Estate Agents' offices in order to get bidders out of the rain. 'The decision to move it in-room was brilliant,' Mr Hajjar said. 'It created a really warm environment for bidders.' The homes under the hammer on King Rd, Hornsby and Kooringal Ave, Thornlie sold for prices well over their respective reserves. The property on King Rd sold for $2.095 million, a price $195,000 over reserve, while 78 Kooringal Ave sold for $2.395 million, $295,000 above its reserve. Mr Hajjar said it was a 'hesitant start' to the bidding, before they 'heated up very quickly.' Fifty-six bids were placed for 78 Kooringal Ave and a staggering 117 bids were placed during the auction for 8 King Rd. MORE: Pub baron's lavish lifestyle while owing $1bn criticised Further out west, a family were reported to be delighted with the sale of their property in Hassall Grove. No. 33 Monica Ave sold over reserve for a price of $1.015 million, with bidding opening at $800,000. Sales agent Meshel Bahnam of Ray White United Group said there were 17 registered bidders, the most he has seen in 'well over 18 months'. 'People are trying to buy before rates change this month,' she said. 'In the end, local first home buyers who have been looking for six months bought the house. 'They are so happy as they keep missing out on auctions,' said Mr Banham. Mr Banham said it was a suburb record price for a three-bedroom, one-bathroom house on a 454 sqm block. Sellers Brooke, Alex and their three children were reported to be contemplating a move to Lake Macquarie for a lifestyle change. Other sales included the auction for 50 Iandra Street, Concord West, which sold to its first bidder, going for a price of $3.51 million. Horwood Nolan founder and director Ben Horwood said interest was strong in the lead up to the auction. 'We had three registered bidders, all who had shown strong interest throughout the campaign,' he said. Mr Horwood said the home's location mostly attracted interest from families.
Daily Telegraph
3 hours ago
- Daily Telegraph
Weekend auction wrap: Sydney family smashes neighbour's record
A home in Sydney's northwest has sold for a suburb record, smashing the price paid for a home owned by the neighbours – the previous highest price in the area. The property on Anthony Rd sold for $4.7 million, setting a new record for a house sale in West Ryde. The auction saw the sellers pcoket a price $300,000 above their $4.4 million reserve. It has come amid rising auction activity that suggests Sydney is due another round of stellar growth in home prices. Auction clearance rates have been above 70 per cent for weeks, with preliminary figures showing nearly three quarters of auctions last week produced a sale. Historically, this kind of success rate over successive weeks has coincided with widespread price rises. Pello Northern Suburbs sales agent Michael Dowling said the West Ryde auction was 'really competitive' with bidding starting at $3.8 million. 'The previous highest sale in West Ryde was the house next door, and that sold for $4.19 about two years ago,' he said. 'So we knew it was going to be better than that, but I didn't think it was going to be $510,000 better than that.' MORE: Aus worse off as RBA rate cut panic sets in Mr Dowling said the home sold to a mother and two sons moving from Cheltenham who wanted a more spacious home that was ready to move in to. 'A lot of people in our area want that move-in ready feel, rather than going through the hassle and the inconvenience of dealing with council,' he said. 'A lot of people just want that finished product now.' MORE: 'Pivotal moment': chance to buy in Sydney for half price Auction clearance rates above 70 per cent have historically correlated with rises in prices across the Sydney market as a whole. Ray White NSW head of auctions Dave McMahon said the first weekend of August saw a 25 per cent decrease in scheduled auctions from the week prior. 'The notable difference was that only half of them proceeded through the day,' he said. 'With stock levels low, agents have been more open to entertaining offers prior with circa 15-20 per cent selling before auction day. 'Despite lower auction numbers today, we continued to see spirited competition from buyers with an average of 5.8 registered and 3.6 actively bidding.' MORE: Where your luxury car can come to dinner 'The decision to move it in-room was brilliant,' Mr Hajjar said. 'It created a really warm environment for bidders.' The homes under the hammer on King Rd, Hornsby and Kooringal Ave, Thornlie sold for prices well over their respective reserves. The property on King Rd sold for $2.095 million, a price $195,000 over reserve, while 78 Kooringal Ave sold for $2.395 million, $295,000 above its reserve. Mr Hajjar said it was a 'hesitant start' to the bidding, before they 'heated up very quickly.' Fifty-six bids were placed for 78 Kooringal Ave and a staggering 117 bids were placed during the auction for 8 King Rd. MORE: Pub baron's lavish lifestyle while owing $1bn criticised Further out west, a family were reported to be delighted with the sale of their property in Hassall Grove. No. 33 Monica Ave sold over reserve for a price of $1.015 million, with bidding opening at $800,000. Sales agent Meshel Bahnam of Ray White United Group said there were 17 registered bidders, the most he has seen in 'well over 18 months'. 'People are trying to buy before rates change this month,' she said. 'In the end, local first home buyers who have been looking for six months bought the house. 'They are so happy as they keep missing out on auctions,' said Mr Banham. Mr Banham said it was a suburb record price for a three-bedroom, one-bathroom house on a 454 sqm block. Sellers Brooke, Alex and their three children were reported to be contemplating a move to Lake Macquarie for a lifestyle change. Other sales included the auction for 50 Iandra Street, Concord West, which sold to its first bidder, going for a price of $3.51 million. Horwood Nolan founder and director Ben Horwood said interest was strong in the lead up to the auction. 'We had three registered bidders, all who had shown strong interest throughout the campaign,' he said. Mr Horwood said the home's location mostly attracted interest from families. MORE: Aus worse off as RBA rate cut panic sets in
